Joseph’s Journey Against Glioblastoma

11/21/2025

Every glioblastoma tumor has a distinct genomic fingerprint—revealing mutations, fusions, or subtypes that can guide personalized treatment.

🧬 Genomic testing helps identify what makes each tumor unique, because one-size-fits-all treatment isn’t enough.

Learn more and sign up for updates about our upcoming testing options. https://bit.ly/42EiGfc

11/21/2025

Columbia researchers show for the first time that focused ultrasound can safely open the blood-brain barrier in children, enhancing delivery of chemotherapy to tumors.

11/21/2025

🚫 No red tape.
✅ No delays.
💯 Funding innovation.

Unravel provides funding focused on innovation so the brightest minds in pediatric cancer research can push bold ideas forward faster and get closer to cures faster!

Want to learn more about all the researchers Unravel supports? Follow this link: https://unravelpediatriccancer.org/science

11/19/2025

11/19/2025

Exciting News!📢 The U.S. FDA has granted ODD to niraparib for the treatment of malignant glioma, including GBM. The designation is supported by the clinical trial interim data reported by the Ivy Brain Tumor Center at Barrow Neurological Institute. ODD is a special status granted by the FDA to medicines intended to treat, diagnose, or prevent rare diseases. This designation provides incentives such as regulatory support, tax credits, and potential market exclusivity to accelerate the development of treatments for patients with rare and life-threatening conditions.

Read here: https://www.ivybraintumorcenter.org/about/newsroom/news/phase-3-gliofocus-study-drug-niraparib-granted-orphan-drug-designation-by-u-s-fda-for-treatment-of-malignant-glioma-including-glioblastoma/

11/19/2025

A recent study published in the journal Cancer investigates how targeted federal initiatives are shaping progress in childhood and adolescent cancer research. The paper outlines how programs like the STAR Act and the Childhood Cancer Data Initiative (CCDI) are helping build infrastructure for biospecimen collection, long-term survivor tracking, and data-sharing across pediatric oncology.

"These efforts are helping ensure that the benefits of precision medicine reach all children and families affected by cancer, while advancing our understanding of the biological and clinical complexity of childhood cancer," write the authors.

This paper clearly illustrates why advocating for these programs is a core component of our policy priorities at Children’s Cancer Cause. The critical and innovative intramural research being done on campus at NIH and NCI has saved countless lives and must continue to be fully funded and unimpeded in its mission to improve the lives of childhood cancer patients, survivors, and families.

Follow the citation in the comments to read the full article.

11/19/2025

11/19/2025

' ReSPECT-GBM is a Featured on the American Brain Tumor Association website: https://bit.ly/3JUYRtt

We’re actively recruiting malignant glioma patients who have already gone through standard treatments like surgery, radiation or chemotherapy and have seen their cancer reappear or grow for our Phase 2 study.

Please visit our website to learn more: www.respect-trials.com/gbm

11/18/2025